S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
$2.38
$2.07
$10.85
$61.05MN/A171,558 shs43,600 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.90
-5.3%
$4.17
$0.61
$9.37
$20.35M1.11.68 million shs531,096 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00%0.00%0.00%0.00%0.00%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%-59.18%-99.22%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-5.28%-10.00%-85.71%-15.89%-9.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
2.2125 of 5 stars
3.54.00.00.01.72.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
3.00
Buy$5.00455.56% Upside

Current Analyst Ratings

Latest HTBX, NEPT, VINC, CHMA, and TLC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/1/2024
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$0.52 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$1.89N/AN/AN/AN/A-187.73%-126.26%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.63
2.63

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
4925.65 millionN/AOptionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
4121.41 million17.00 millionNot Optionable

HTBX, NEPT, VINC, CHMA, and TLC Headlines

SourceHeadline
AACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survivalAACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survival
fiercebiotech.com - April 18 at 12:36 PM
Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)
americanbankingnews.com - April 16 at 2:40 AM
Agendia’s BluePrint Included in German Oncology Group GuidelinesAgendia’s BluePrint Included in German Oncology Group Guidelines
finance.yahoo.com - April 12 at 9:45 AM
Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACRVaccines, Next-Gen Approaches Target the Toughest Cancers: AACR
biospace.com - April 12 at 9:45 AM
The Rise of Zyn: The Oral Nicotine Product Going ViralThe Rise of Zyn: The Oral Nicotine Product Going Viral
finance.yahoo.com - April 10 at 4:08 PM
Vincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersVincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners
markets.businessinsider.com - April 10 at 9:44 AM
Vincerx Pharmas (VINC) "Overweight" Rating Reaffirmed at Cantor FitzgeraldVincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - April 10 at 4:14 AM
Vincerx (VINC) Tumbles on Results From Cancer Therapy StudyVincerx (VINC) Tumbles on Results From Cancer Therapy Study
zacks.com - April 9 at 2:36 PM
ACOR, HUBC and DATS among pre-market losersACOR, HUBC and DATS among pre-market losers
msn.com - April 9 at 9:19 AM
Vincerx in selloff after early-stage data for cancer therapyVincerx in selloff after early-stage data for cancer therapy
msn.com - April 9 at 9:19 AM
Cantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)Cantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)
marketbeat.com - April 9 at 8:49 AM
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
investorplace.com - April 9 at 8:40 AM
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
globenewswire.com - April 8 at 4:30 PM
FY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)FY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)
marketbeat.com - April 4 at 9:13 AM
Q1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink PartnrsQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrs
marketbeat.com - April 3 at 6:00 AM
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023
investorplace.com - April 2 at 8:06 AM
Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
finanznachrichten.de - April 1 at 4:30 PM
Vincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor FitzgeraldVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgerald
marketbeat.com - April 1 at 12:23 PM
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
finance.yahoo.com - April 1 at 10:47 AM
Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close LookVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
finance.yahoo.com - March 29 at 8:49 PM
Vincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024Vincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024
marketwatch.com - March 29 at 3:48 PM
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
globenewswire.com - March 29 at 3:20 PM
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%
marketbeat.com - March 28 at 8:34 AM
Vincerx Pharma (VINC) Set to Announce Earnings on TuesdayVincerx Pharma (VINC) Set to Announce Earnings on Tuesday
marketbeat.com - March 25 at 7:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Heat Biologics logo

Heat Biologics

NASDAQ:HTBX
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Neptune Wellness Solutions logo

Neptune Wellness Solutions

NASDAQ:NEPT
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Taiwan Liposome logo

Taiwan Liposome

NASDAQ:TLC
Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.
Vincerx Pharma logo

Vincerx Pharma

NASDAQ:VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.